Table 22 Top 10 pairs of drugs with their correlation with subtype 10 of breast cancer, considering both combined and individually
From: Computationally repurposing drugs for breast cancer subtypes using a network-based approach
Drug1 | Drug2 | C. Cor. | Cor. 1 | Cor. 2 | C. Rank | Rank 1 | Rank 2 |
|---|---|---|---|---|---|---|---|
Tadalafil | Telatinib | − 0.86 | − 0.55 | − 0.53 | 1 | 47 | 61 |
Bitopertin | Lidocaine | − 0.85 | − 0.66 | − 0.57 | 2 | 2 | 35 |
Anecortave-Acetate | Goserelin-Acetate | − 0.84 | − 0.56 | − 0.52 | 3 | 38 | 64 |
Finasteride | Tadalafil | − 0.84 | − 0.60 | − 0.55 | 4 | 16 | 47 |
Bitopertin | Raclopride | − 0.83 | − 0.66 | − 0.57 | 5 | 2 | 36 |
SDZ-NKT-343 | Goserelin-acetate | − 0.83 | − 0.59 | − 0.52 | 6 | 24 | 64 |
Goserelin-Acetate | Vardenafil | − 0.81 | − 0.52 | − 0.48 | 7 | 64 | 96 |
Favipiravir | Isbufylline | − 0.81 | − 0.59 | − 0.58 | 8 | 25 | 28 |
Bisoprolol | Finasteride | − 0.80 | − 0.61 | − 0.60 | 9 | 12 | 16 |
Finasteride | Garcinol | − 0.80 | − 0.60 | − 0.55 | 10 | 16 | 48 |